Bausch Health Companies, Inc. (BHC)
|Net Income (ttm)||43.00M|
|Day's Range||5.99 - 6.30|
|52-Week Range||4.00 - 29.59|
|Price Target||12.61 (+109.8%)|
|Earnings Date||Aug 9, 2022|
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Sal... [Read more...]
In 2021, BHC's revenue was $8.43 billion, an increase of 5.07% compared to the previous year's $8.03 billion. Losses were -$948.00 million, 69.3% more than in 2020.Financial Statements
According to 10 analysts, the average rating for BHC stock is "Buy." The 12-month stock price forecast is 12.61, which is an increase of 109.82% from the latest price.
Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside carefully.
LAVAL, Quebec , Aug. 10, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's J...
Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.
CMS Issues New Specific ICD-10 Code K76.82 for HE LAVAL, QC , Aug. 10, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharma...
Investors are increasingly realizing the scope of the turnaround project CEO Thomas Appio has on his plate.
Bausch (BHC) delivered earnings and revenue surprises of -38.20% and 3.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health cut its revenue estimate for the year to a range between $8.05 billion and $8.22 billion, from a $8.25 billion to $8.40 billion earlier range.
Shares of Bausch Health Cos. Inc. BHC, +4.47% tumbled 11.8% in premarket trading on Tuesday after the company missed revenue expectations for the quarter, reported an unexpected loss, and lowered its re...
Revenues of $1.967 billion Company to appeal anticipated court decision and vigorously defend XIFAXAN intellectual property Balance sheet continues to improve with early retirement of $481 million of lo...
Shares of Bausch + Lomb Corp. BLCO, +4.15% were up 3.1% in premarket trading on Thursday after the eyecare company outperformed earnings and revenue expectations in the second quarter of 2022. Bausch ha...
An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street is still digesting the legal drama impacting embattled pharmaceutical firm Bausch Health (NYSE: BHC ). The company has promised to pursue all available options regarding an unfavorable decis...
Bausch Health Companies ( BHC , Financial) received a devastating body blow on Thursday when a U.S. federal court judge invalidated some key patents on its largest product Xifaxan for the treatment of i...
The heavy selling pressure might have exhausted for Bausch (BHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in rev...
Bausch Health stock tumbles toward lowest close since 1995 after confirming disappointing court ruling
Shares of Bausch Health Companies Inc. BHC, -6.53% dropped 7.8% in morning trading Friday, toward a 27-year low, after the drug and medical device maker confirmed a disappointing court decision regardin...
A patent-court loss sent investors scurrying to the exits.
Bausch stock fell more than 50% Thursday before trading was halted.
-- Company to Appeal Expected Court Decision on Certain XIFAXAN® Patents – LAVAL, Quebec , July 28, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business S...
Shares of Bausch Health Companies Inc. BHC, -50.29% suffered a near-record plunge of 50.3% in volatile afternoon trading Thursday before a trading halt, after Bloomberg reported that some of the drug an...
While pharmaceutical companies often face great risks in the clinical testing arena, they can also suffer extraordinary setbacks in the courtroom, as Bausch Health (NYSE: BHC ) unfortunately demonstrate...
LAVAL, Quebec , July 27, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter financial results on Tuesday, Aug. 9, 2022. Bausch Health wil...
For Third Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC , July 13, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bau...